Sign In
Buy STOK
$28.86
-1.18 (-3.93%)
At Close: Jul 31, 2026
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
02:05pm, Tuesday, 27'th Jan 2026
New Headquarters Will Support Company's Work to Deliver zorevunersen, a Potential Disease-Modifying Medicine, to Patients with Dravet Syndrome and Expansion of Research Efforts Lease is One of the Lar
Campbell & CO Investment Adviser LLC Acquires Shares of 30,418 Stoke Therapeutics, Inc. $STOK
04:55am, Wednesday, 21'st Jan 2026
Campbell and CO Investment Adviser LLC bought a new position in Stoke Therapeutics, Inc. (NASDAQ: STOK) in the undefined quarter, according to the company in its most recent Form 13F filing with the S
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Friday, 16'th Jan 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity
08:49am, Thursday, 15'th Jan 2026
Stoke Therapeutics' TANGO ASO platform can upregulate the functional allele, targeting haploinsufficiency diseases like Dravet and ADOA. This approach gives Zorevunersen disease-modifying features, wh
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:01pm, Tuesday, 06'th Jan 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Reviewing Cortex Pharmaceuticals (OTCMKTS:RSPI) & Stoke Therapeutics (NASDAQ:STOK)
01:32am, Monday, 22'nd Dec 2025
Cortex Pharmaceuticals (OTCMKTS:RSPI - Get Free Report) and Stoke Therapeutics (NASDAQ: STOK - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compar
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts
01:32am, Monday, 22'nd Dec 2025
Stoke Therapeutics, Inc. (NASDAQ: STOK - Get Free Report) has earned a consensus rating of "Buy" from the ten analysts that are presently covering the company, MarketBeat reports. Two investment analy
Assenagon Asset Management S.A. Has $21.16 Million Position in Stoke Therapeutics, Inc. $STOK
03:27am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. raised its holdings in Stoke Therapeutics, Inc. (NASDAQ: STOK) by 67.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Excha
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Tuesday, 16'th Dec 2025
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117%
01:15pm, Tuesday, 16'th Dec 2025
Biotech leader Stoke stock is running up toward a new buy point. The company's revenue surged 117% in Q3.
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell?
08:59pm, Wednesday, 10'th Dec 2025
Barry Ticho, Chief Medical Officer at Stoke Therapeutics (STOK +12.08%), executed an option exercise and open-market sale of 5,358 common shares for a total consideration of approximately $167,115 on
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in sei
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
07:30am, Monday, 01'st Dec 2025
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R
